O1-12-6 - Retrospective analysis on usefulness of somatostatin receptor scintigraphy for neuroendocrine neoplasm

Abstract

Somatostatin receptor scintigraphy (SRS) has been widely used for diagnosis and treatment of neuroendocrine neoplasm (NEN) for 20 years worldwide. SRS has been approved for clinical use under public health insurance from January 2016 in Japan. We retrospectively reviewed medical records of patients who received SRS from January 2016 to January 2017. Result: Eight patients (4 male and 4 female) received SRS, and the median age was 56 years old (37-72). Of whom, five patients were diagnosed as NEN, including one functioning pancreatic and duodenal NEN of multiple endocrine neoplasia type 1. Remaining four were non-functioning NEN, originated from rectum (one patient with WHO classification grade 2) and pancreas (2 with grade 2 and 1 with grade 3). Positive uptake in SRS was detected in all NEN patients except for one patient with grade 3. SRS revealed that the primary tumor site was rectum in a patient with severe liver involvement. Two patients with pancreatic NEN were treated with somatostatin analogue according to positive results of SRS and obtained good disease control. Three patients later diagnosed as non-NEN showed negative uptake in SRS. As reported so far, well-differentiated NEN was positive for SRS. SRS was useful to determine whether somatostatin analogue should be administered or not, and to explore a location of primary lesion. SRS should be considered for well differentiated NEN.